Opiate withdrawal syndrome in buprenorphine abusers admitted to a rehabilitation center in Tunisia

Derbel, Ines; Ghorbel, Asma; Akrout, Feriele Messadi; Zahaf, Abdelmajid

doi:10.4314/ahs.v16i4.24

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concerns associated with buprenorphine therapy include: 1. a series of active metabolites that are full MOR agonists (Moody et al, 2011;Häkkinen et al, 2012;Tompkins et al, 2014); 2. subversion for recreational purposes or to relive symptoms of dependence (Nigan et al, 1994;Eissenberg et al, 1996;Tompkins et al, 2014;Derbel et al, 2016), and 3. respiratory depression either in patients with compromised respiratory function, or when buprenorphine is combined with benzodiazepines (FDA, 2012(FDA, , 2018Schuman-Olivier et al, 2013;Jones and McAninch, 2015;Dowell et al, 2016;Hirschtritt et al, 2017). Critically, preclinical models can be used to assess these high risk circumstances.…”

Section: Rm1490 Comparison To Buprenorphinementioning

confidence: 99%

A Novel Maintenance Therapeutic for Opioid Use Disorder

Youngblood¹,

Li²,

Gehlert³

et al. 2021

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Buprenorphine hydrochloride, morphine pellets (75 mg each of base), and morphine sulfate were provided by the NIDA drug supply program. DAMGO, forskolin, IBMX, naloxone hydrochloride, fentanyl, and diazepam were obtained from Sigma Aldrich, St Louis, MO.Carfentanil was obtained from Cayman Chemical C Ham-F12 and FBS were purchased from Invitrogen, Carlsbad, CA. RM1049 and RM1490 were provided by R2M Pharma, South San Francisco, CA and synthesized as previously reported (Medina et al., 2019). Naloxone, morphine and fentanyl were dissolved in 0.9% saline; stock solutions of the other compounds were prepared by dissolving in DMSO and kolliphor and then diluting with 0.9% saline to working concentrations, which contained 1% or less of DMSO and kolliphor. Vehicle control solutions consisted of 0.9% saline, 1% DMSO, and 1% kolliphor. Unless otherwise stated injection were subcutaneous (s.c.) at 3 to 5 ml/kg. Cell Culture and in-vitro assays:MOR cAMP assays: CHO Tag-lite human MOR stable cell line from Cisbio (NCBI accession number: NM_000914.3, Bedford, MA) were seeded and grown to approximately 80% confluence in Ham F-12 with 10% FBS, 50 U/ml penicillin, 50 µg/ml streptomycin, 2 mM Hepes, and 1 mg/ml geneticin (Invitrogen, Carlsbad, CA). Cells were then harvested using accutase (Corning, Corning, NY), centrifuged at 1300 RPM for 5min, and plated at 5000 cells per 5 μL per well in a 5x dilution of stimulation buffer consisting of the HTRF cAMP Gi kit, water and IBMX at 0.5 mM (Cisbio, Bedford, MA) in white HTRF low volume 384-well plates (Cisbio, Bedford, MA). Plates were then incubated at 37°C in 5% CO 2 for 10minutes. For the This article has not been copyedited and formatted. The final version may differ from this version.

show abstract

Section: Rm1490 Comparison To Buprenorphinementioning

confidence: 99%

A Novel Maintenance Therapeutic for Opioid Use Disorder

Youngblood¹,

Li²,

Gehlert³

et al. 2021

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

“…The European Monitoring Centre for Drugs and Drug Addiction annual reviews have revealed large differences in OAT implementation and outcomes in different countries. 69 In some countries like Tunisia and Georgia 70,71 buprenorphine is not approved to treat OUD and drug use is criminalized. In contrast, some countries like Finland and Sweden have buprenorphine regulatory conditions similar to France but, diversion of buprenorphine has emerged as a F I G U R E 4 diagram of second-order articles by location.…”

Section: Different Representations Of Problems In Different Localesmentioning

confidence: 99%

How policy problems and solutions travel in the scientific literature: An international scientometric analysis of the French Model of opioid use disorder care

Gamage

Chiu

Ryk

et al. 2023

Evaluation Clinical Practice

View full text Add to dashboard Cite

Rationale The 2007 article ‘Why buprenorphine is so successful in treating opiate addiction in France’ has been widely cited to promote various solutions to growing opioid‐related harms across multiple jurisdictions globally. However, selective promotion of aspects of the French experience or promotion of the French experience without considering relevant contextual factors may inform policies that will not bring the same outcomes as in France, including the introduction of possible unintended negative consequences. The scientific literature is one important arena in which policy solutions are identified, evaluated, promoted and disseminated. Scientific communication of the French opioid use disorder care model offers a timely and relevant example through which to examine how problem representations travel and to consider the effects of these representations. Aims and Objectives We aimed to explore where, when, and how the content of this 2007 index article has travelled through the scientific literature. Method Informed by Bacchi's understanding of problem representation, we conducted a scientometric analysis of the index article. This included categorical analyses using a combination of citation metadata and content data to identify patterns across locations and time. Results Researchers in the United States and Anglophone countries affirmatively cited specific index study content, namely less stringent regulations and positive outcomes, such as reductions in overdose deaths and increases in buprenorphine utilization. These citations were more common after 2015 and were more likely to be in discussion sections of nonempirical publications. Researchers from France cited similar content but did so nonaffirmatively, and throughout the study period. Likewise, the French citations were mostly agenda‐setting citations in the introductory sections of empirical studies. US studies received the highest attention based on number of citations and Altmetric scores. Conclusion US studies, by focusing on less stringent buprenorphine regulation as the primary solution of concern, have constructed opioid‐related harms as a problem of restrictive regulations for buprenorphine. This selective focus on regulation, as opposed to other aspects of the French Model elucidated in the index article such as changes pertaining to the values and financing that structure health service delivery, represents an important missed opportunity for evidence‐informed policy learning across jurisdictions.

show abstract

“…; while Tunisian researchers report on opiate withdrawal syndrome in buprenorphine abusers admitted to a rehabilitation center 23 . The section ends with a rhetorical question: Does exercise alleviate depression related systemic inflammation in chronic obstructive pulmonary disease patients?…”

mentioning

confidence: 99%

Child, reproductive, mental health; infections and NCDs in the African environment

Tumwine¹

2016

Afr H. Sci.

View full text Add to dashboard Cite

Opiate withdrawal syndrome in buprenorphine abusers admitted to a rehabilitation center in Tunisia

Cited by 4 publications

References 26 publications

A Novel Maintenance Therapeutic for Opioid Use Disorder

A Novel Maintenance Therapeutic for Opioid Use Disorder

How policy problems and solutions travel in the scientific literature: An international scientometric analysis of the French Model of opioid use disorder care

Child, reproductive, mental health; infections and NCDs in the African environment

Contact Info

Product

Resources

About